Edition:
United Kingdom

Bill Berkrot

Amazon to buy PillPack in potentially disruptive drug retail push

28 Jun 2018

Amazon.com Inc said on Thursday it would buy small online pharmacy PillPack, a move that will put the world's biggest online retailer in direct competition with drugstore chains, drug distributors and pharmacy benefit managers. | Video

Medical device maker Stryker makes takeover approach to Boston Scientific: WSJ

11 Jun 2018

Medical device maker Stryker Corp has made a takeover approach to rival Boston Scientific Corp, the Wall Street Journal reported on Monday, a combination that would give Stryker a strong position in stroke-preventing heart products.

Celgene profit tops estimates; clarifies path for key MS drug

04 May 2018

Celgene Corp reported much-needed, stronger-than-expected first quarter results as profit and sales of several drugs exceeded Wall Street forecasts, and the U.S. biotechnology company said it would re-apply for approval of an important multiple sclerosis treatment in early 2019.

Regeneron/Sanofi cut heart drug price to $4,500-$6,600 for Express Scripts

01 May 2018

Regeneron Pharmaceuticals Inc and Sanofi SA will slash the price of their expensive cholesterol drug for Express Scripts Holdings Co customers in exchange for greater patient access, with some savings to be shared with consumers, the companies said on Tuesday.

Pfizer first quarter results miss estimates as key drug sales fall short

01 May 2018

NEW YORK Pfizer Inc on Tuesday reported lower-than-expected first-quarter revenue as demand for some key drugs and international sales fell short of estimates, sparking a 5.1 percent drop in shares of the largest U.S. drugmaker. | Video

Regeneron/Sanofi to cut price of heart drug in Express Scripts deal

01 May 2018

May 1 Regeneron Pharmaceuticals and Sanofi will cut the net price of their expensive cholesterol drug for Express Scripts customers in exchange for greater patient access, with some savings to be shared with consumers, the companies said on Tuesday.

Bristol-Myers raises 2018 forecast, some sales disappoint

26 Apr 2018

NEW YORK Bristol-Myers Squibb Co on Thursday significantly raised its full-year earnings forecast even as first-quarter sales of some medicines fell short of expectations and sent shares of the U.S. drugmaker down almost 1 percent.

Survival data boosts Merck's Keytruda lead in lung cancer

16 Apr 2018

NEW YORK/CHICAGO Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival in newly-diagnosed patients with advanced non-small cell lung cancer in a closely-watched study, cementing its lead position over Bristol-Myers Squibb Co and others in the most lucrative oncology market.

Merck, Bristol-Myers immunotherapies impress in key lung cancer trials

16 Apr 2018

Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival versus chemotherapy alone in newly-diagnosed patients with advanced non-small cell lung cancer in a highly-anticipated study that appears to cement the company's lead in the most lucrative oncology market.

Merck, Bristol-Myers immunotherapies impress in key lung cancer trials

16 Apr 2018

April 16 Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival versus chemotherapy alone in newly-diagnosed patients with advanced non-small cell lung cancer in a highly-anticipated study that appears to cement the company's lead in the most lucrative oncology market.

World News